BTG Appoints Peter Chambré as Non-Executive Director
London, UK, 27 September 2006: BTG plc (LSE: BGC), the medical innovations company, today announces the appointment of Peter Chambré as non-executive director on 26 September 2006.
Peter was Chief Executive Officer of Cambridge Antibody Technology Group plc from 2002 until its recent acquisition by AstraZeneca plc. Previously he was Chief Operating Officer of Celera Genomics Group and Chief Executive of Bespak plc. He is currently a non-executive director of Spectris plc, the precision instrumentation and controls company.
Sir Brian Fender, BTG's Chairman, commented: "I am delighted to welcome Peter to BTG's Board of Directors. He has tremendous international experience in the life sciences sector that will be of benefit to the Company as we further develop our business."
There are no further details to be disclosed in relation to paragraph 9.6.13R of the Financial Services Authority Listing Rules.
Director of Investor Relations
+44 (0)20 7575 1741
Chief Financial Officer
+44 (0)20 7575 1591
+44 (0)20 7831 3113
BTG in-licenses, develops and commercialises pharmaceuticals and other medical technologies. With a substantial and growing revenue stream of royalties and milestone payments from out-licensed products, BTG continues to strengthen its pipeline of preclinical and clinical development programmes. Active in the fields of oncology, diseases of ageing, neuroscience, drug repositioning and medical devices, BTG works from its offices in London, Philadelphia and Osaka with a global partner network of healthcare companies and research organisations. For further information, visit: www.btgplc.com.Back to press releases